From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1984
Last Reported 2006
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 5
Disease Relevance 1.88
Pain Relevance 0.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (AMPD1) small molecule metabolic process (AMPD1)
Anatomy Link Frequency
erythrocytes 1
muscle 1
stem cell 1
AMPD1 (Homo sapiens)
Pain Link Frequency Relevance Heat
adenocard 9 100.00 Very High Very High Very High
aspirin 4 100.00 Very High Very High Very High
diclofenac 2 100.00 Very High Very High Very High
cytokine 1 96.48 Very High Very High Very High
antagonist 1 95.76 Very High Very High Very High
agonist 1 94.00 High High
abdominal pain 1 89.12 High High
palliative 1 88.60 High High
cINOD 2 75.32 Quite High
ischemia 12 21.44 Low Low
Disease Link Frequency Relevance Heat
Porphyria 2 97.90 Very High Very High Very High
Lymphatic System Cancer 10 96.44 Very High Very High Very High
Acidosis 2 95.96 Very High Very High Very High
Abdominal Pain 1 89.12 High High
Vomiting 1 87.84 High High
Muscle Weakness 1 87.04 High High
Constipation 1 85.68 High High
Disease 6 79.36 Quite High
INFLAMMATION 2 75.08 Quite High
Mycosis Fungoides 2 66.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Less accumulation of substrate for AMP deaminase or specific inactivation of AMP deaminase both could explain stabilization of the adenine nucleotide pool and reduced ammonia production [27].
Positive_regulation (accumulation) of AMP deaminase
1) Confidence 0.44 Published 2005 Journal BMC Physiol Section Body Doc Link PMC1187899 Disease Relevance 0.10 Pain Relevance 0
Alterations in substrate utilization can influence muscle pH during contraction, and hence the activation of AMP deaminase, See [27].
Positive_regulation (activation) of AMP deaminase in muscle
2) Confidence 0.29 Published 2005 Journal BMC Physiol Section Body Doc Link PMC1187899 Disease Relevance 0.05 Pain Relevance 0
Acute intermittent porphyria is caused by an inherent error of porphyrin metabolism characterized by a deficiency of porphobilinogen deaminase and increased activity of delta-aminolevulinic acid synthase, key enzymes necessary for the biosynthesis of heme.
Positive_regulation (increased) of deaminase associated with porphyria
3) Confidence 0.01 Published 1984 Journal Pharmacotherapy Section Abstract Doc Link 6377248 Disease Relevance 0.60 Pain Relevance 0.09
Deaminase adenosine activity in erythrocytes is inhibited by ASA and diclofenac but increased by nimesulide.
Positive_regulation (increased) of Deaminase in erythrocytes associated with aspirin, adenocard and diclofenac
4) Confidence 0.01 Published 2006 Journal Pol. Arch. Med. Wewn. Section Abstract Doc Link 18652275 Disease Relevance 0.15 Pain Relevance 0.55
Other novel agents include the interleukin (IL)-2 fusion toxin (ONTAK), pentostatin (a potent adenosine deaminase inhibitor), histone deacetylase inhibitors such as depsipeptide, NF-kappaB inhibitors, cytokine receptor antagonists, immunomodulatory therapies and allogeneic stem cell therapy.
Positive_regulation (potent) of deaminase in stem cell associated with adenocard, antagonist and cytokine
5) Confidence 0.00 Published 2003 Journal Leuk. Lymphoma Section Abstract Doc Link 15202526 Disease Relevance 0.98 Pain Relevance 0.28

General Comments

This test has worked.

Personal tools